needed, additional biological and radiologic examinations were performed. Clinical evaluation of each patient, at baseline and during treatment, was always performed by the same clinician. The main criterion of IFX efficacy in our patients was the static physician global assessment tool. Disease activity and severity were also assessed using the Hurley score, visual analog pain scale, and Dermatology Life Quality Index (Table I) . [2] [3] [4] Thirteen patients were enrolled and no adverse events were observed, except for 1 patient who developed paradoxical pustular psoriasis. An objective response was observed in 9 patients. We observed worsening of disease in 4 patients, who tended to have the highest Dermatology Life Quality Index score (Table I) . Two patients were underdosed with drug trough levels less than 2 g/mL and 1 of them developed antibodies against IFX (Table I) . High baseline levels of IL-6 and hs-CRP were predictive of nonresponse to IFX (P ¼ .0168 and .0112, respectively, using Mann-Whitney test) (Table II) . Inversely, all patients with IL-6 level below 5 (area under the curve 0.9167; 95% confidence interval 0.7423-1.091; P ¼ .02064) responded to the treatment. The clinical severity score at baseline, IL-1, and TNF-serum levels did not appear as a good predictive markers of response to IFX-therapy (Table II) . A correlation was observed between serum levels of hs-CRP and IL-6 (r ¼ 0.79, P ¼ .0005 using the Pearson correlation test). No similar data were observed with hs-CRP/IL-1 (r ¼ 0.1, P ¼ .74), hs-CRP/TNF (r ¼ 0.12, P ¼ .65), or IL-1/IL-6 (r ¼ 0.01, P ¼ .73). We did not observe any correlation between response to treatment and kinetics of IL-6, hs-CRP, IL-1, and TNF-, with no significant change in their levels during IFX therapy (data not shown).
These results suggest that initial levels of hs-CRP and IL-6 are potential response markers for IFX treatment in HS. Additional studies are needed to determine whether these markers can predict the response to other TNF inhibitors. As there are multiple confounding factors when using CRP levels, 5 it is possible that IL-6 has greater reliability for predicting the response to treatment in patients with HS. Secondary endpoints included changes from baseline in pruritus and vulvar burning using visual analogue scales (VAS) and change in Investigator's Global Assessment (IGA) of the severity of the disease (0 to 3 scale). Twelve of the 15 participants completed the protocol, 2 participants were lost to follow-up before the second PRP treatment, and another refused post-treatment biopsy. Of the 12 patients who completed the protocol, the dermatopathologists determined that 7 had decreased inflammation on their post-treatment biopsies (Figs 1 and 2 The effectiveness of PRP is based on its high level of growth factors such as PDGF, TGF-, and EGF. These growth factors are important in modulating mesenchymal cell proliferation, and extracellular matrix synthesis during healing. PRP has shown to be effective at propagating new healthy tissue growth in a wide range of medical conditions such as diabetic foot ulcers, venous stasis ulcers, and tendonopathy. [1] [2] [3] The vast majority of published literature shows that autologous PRP has minimal risk of scar tissue formation or serious adverse events (SAEs). Previously, 1 study examined injections of a combination of PRP and fat-derived mesenchymal cells in 15 women with VLS. 4 The authors reported that ''all patients reported total disappearance of pain and symptoms.'' However, a significant limitation of the study was that 2 concurrent interventions were performed, which limited the ability to determine which intervention was efficacious or necessary. In addition, no objective measures of efficacy were used. In contrast, our study used an objective endpoint (decrease in histopathologic inflammation) measured by masked evaluators. Limitations of this study are the small sample size, lack of placebo control, and short-term follow-up. However, the statistically significant results suggest that PRP decreased histopathologic inflammation in women with VLS without the potential side effects associated with topical or systemic immunomodulators. 
